International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 microg (8 MIU) and Betaseron/-Betaferon 500 microg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Trial Profile

International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 microg (8 MIU) and Betaseron/-Betaferon 500 microg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Interferon beta-1b (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BEYOND
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.
  • Most Recent Events

    • 12 Oct 2015 Results published in the JAMA Neurology
    • 01 Feb 2012 Results reporting neutralising antibody titres published in the Multiple Sclerosis Journal.
    • 10 Sep 2009 Results investigating the effects of treatment on the incidence of depression have been presented at 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top